Tranexamoyl Dipeptide-23 is a synthetic tripeptide with sequence Txa-Pro-Ser (Tranexamil-PS; TXA-PS) found by screening α-MSH (α-Melanocyte-Stimulating Hormone) inhibitory activity of Tranexamic acid derivative peptides. Its activity was better than Arbutin and Ascorbyl Glucoside, well-known skin whitening agents.
Tranexamoyl Dipeptide-23 inhibits tyrosinase, one of the critical enzymes involved in melanin production. It also lessens the expression of MITF (microphthalmia-associated transcription factor) responsible for the differentiation and proliferation of melanocytes (melanin-producing cells).
Tranexamoyl Dipeptide-23 is a derivative of Tranexamic acid (TXA), a hemostatic drug recently used as a skin-whitening agent in topical applications. TXA modification Dipeptide-23 improves its stability in formulations and enhances effectivity. Thanks to its small molecule size, it exhibits excellent skin permeability and an increased penetration rate. Its dual action mechanism leaves a significant skin-whitening effect, fighting against hyperpigmentation, melasma, and dark spots.
Combined with other skin-whitening amino acids and peptides, especially with Tranexamic acid and similar Tranexamoyl- and Nicotinyl-peptides, Tranexamoyl Dipeptide-23 potentiates their action and improves the total effectivity of the product. Its cytotoxicity studies showed that this peptide is a safe ingredient for skincare formulations.